Pharmacological intervention in autoimmune diseases: Exploring new drug targets
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Imagine a class of diseases where the body's own defense system becomes its worst enemy that is the paradox confronting everyone who treats autoimmune conditions [1]. This research evaluated four novel pharmacological agents targeting distinct immunological pathways in patients with rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and multiple sclerosis across two Swiss academic medical centers between October 2024 and April 2025. We enrolled 184 participants and randomly assigned them to receive one of four investigational compounds (ZH-Alpha, a JAK1/3 inhibitor; ZH-Beta, an IL-17A inhibitor; ZH-Gamma, an anti-CD20 monoclonal antibody; or ZH-Delta, a CTLA4-Ig fusion protein) or methotrexate as an active comparator. After 24 weeks of treatment, each drug demonstrated a unique efficacy profile across autoimmune parameters. ZH-Alpha showed the strongest TNF-α suppression (82.3%) and joint protection (76.2%), making it particularly effective for rheumatoid arthritis with a disease activity score reduction of 48.7%. ZH-Beta excelled in IL-17 inhibition (84.2%) and skin improvement (78.3%), translating to a 62.4% disease activity reduction in psoriasis patients. ZH-Gamma achieved the highest B-cell depletion (87.2%) and was most effective in systemic lupus, reducing disease activity by 54.7%. ZH-Delta demonstrated balanced efficacy across multiple parameters with particular strength in T-regulatory cell expansion (82.3%) and performed best in multiple sclerosis with a 52.4% disease activity improvement. All four compounds outperformed methotrexate across their respective target conditions. Safety profiles differed meaningfully: ZH-Gamma carried the highest infection risk (42.6%) and cytopenia rate (38.7%), while ZH-Beta showed the most favorable overall safety with minimal serious adverse events. These findings support a precision medicine approach to autoimmune disease management where drug selection is guided by the predominant immunological pathway driving each patient's condition rather than empiric one-size-fits-all prescribing.
Fields of Study & Subjects
Rheumatoid Arthritis Research and Therapies
Psoriasis: Treatment and Pathogenesis
Systemic Lupus Erythematosus Research
Publication details
- Journal / source
- International Journal of Pharmacology and Pharmaceutical Sciences
- Volume
- 8
- Issue
- 1
- Pages
- 17–22
- Publication date
- 1 January 2026
- Language
- EN